var data={"title":"Neuropsychiatric manifestations of systemic lupus erythematosus","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"topicTitle\">Neuropsychiatric manifestations of systemic lupus erythematosus</div><dl id=\"topicContributors\"><dt><span> </span>Author:</dt><dd><a href=\"https://www.uptodate.com/contents/neuropsychiatric-manifestations-of-systemic-lupus-erythematosus/contributors\" class=\"contributor contributor_credentials\">Peter H Schur, MD</a></dd><dt><span> </span>Section Editors:</dt><dd><a href=\"https://www.uptodate.com/contents/neuropsychiatric-manifestations-of-systemic-lupus-erythematosus/contributors\" class=\"contributor contributor_credentials\">Michael J Aminoff, MD, DSc</a></dd><dd><a href=\"https://www.uptodate.com/contents/neuropsychiatric-manifestations-of-systemic-lupus-erythematosus/contributors\" class=\"contributor contributor_credentials\">Jonathan M Silver, MD</a></dd><dt><span> </span>Deputy Editors:</dt><dd><a href=\"https://www.uptodate.com/contents/neuropsychiatric-manifestations-of-systemic-lupus-erythematosus/contributors\" class=\"contributor contributor_credentials\">Janet L Wilterdink, MD</a></dd><dd><a href=\"https://www.uptodate.com/contents/neuropsychiatric-manifestations-of-systemic-lupus-erythematosus/contributors\" class=\"contributor contributor_credentials\">David Solomon, MD</a></dd></dl><p class=\"disclosureLink\"><a href=\"https://www.uptodate.com/contents/neuropsychiatric-manifestations-of-systemic-lupus-erythematosus/contributor-disclosure\" class=\"contributor contributor_credentials\">Contributor Disclosures</a></p><div id=\"reviewProcess\"><span>All topics are updated as new evidence becomes available and our <a href=\"https://www.uptodate.com/home/editorial-policy\" target=\"_blank\" class=\"policy policy_editorialpolicy\">peer review process</a> is complete.</span></div><div id=\"literatureReviewDate\"><span class=\"emphasis\">Literature review current through:</span>&#160;Feb 2018.&#160;&#124;&#160;<span class=\"emphasis\">This topic last updated:</span>&#160;Nov 18, 2014.</div><div id=\"topicWhatsNewContainer\"></div><div id=\"topicText\"><p class=\"headingAnchor\" id=\"H1\"><span class=\"h1\">INTRODUCTION</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Central nervous system neuropsychiatric lupus refers to the various psychiatric and neurologic manifestations that develop secondary to involvement of the CNS in patients with systemic lupus erythematosus (SLE). These clinical features are characterized by some investigators as either diffuse (eg, encephalopathy, coma, depression, and psychosis) or complex (eg, encephalopathy with stroke or seizure, and psychiatric presentation with stroke or seizure) [<a href=\"https://www.uptodate.com/contents/neuropsychiatric-manifestations-of-systemic-lupus-erythematosus/abstract/1\" class=\"abstract_t\">1</a>]. Disturbances of mental function are the most common symptom.</p><p>Because of the varied diagnostic criteria associated with these manifestations, the American College of Rheumatology (ACR) has formulated case definitions, reporting standards, and diagnostic testing recommendations for the 19 neuropsychiatric SLE syndromes (<a href=\"image.htm?imageKey=RHEUM%2F51238\" class=\"graphic graphic_table graphicRef51238 \">table 1</a>)&nbsp;[<a href=\"https://www.uptodate.com/contents/neuropsychiatric-manifestations-of-systemic-lupus-erythematosus/abstract/2\" class=\"abstract_t\">2</a>]. The full definitions can be found at the following Internet address: <a href=\"http://www.rheumatology.org/publications/ar/1999/aprilappendix.asp&amp;token=jiLeZupnXw1GrBzHkB5U2V6IlXRg3fM1hCfU6HTwDAlgsXuze3oetbbp0RVZIiHIsoTKAc3Q/EwvDjfVCqKYSaY2/oVHd8m4ezJenIdvc+A=&amp;TOPIC_ID=4863\" target=\"_blank\" class=\"external\">www.rheumatology.org/publications/ar/1999/aprilappendix.asp</a>.</p><p>A psychiatric disturbance due to CNS lupus is a diagnosis of exclusion; all other possible causes of the observed symptoms must therefore be considered, including infection, electrolyte abnormalities, renal failure, drug effects, mass lesions, arterial emboli, and primary psychiatric disorders (such as bipolar disorder or severe stress disorder resulting from a chronic and life-threatening disease) [<a href=\"https://www.uptodate.com/contents/neuropsychiatric-manifestations-of-systemic-lupus-erythematosus/abstract/3\" class=\"abstract_t\">3</a>]. One clue to the diagnosis is that most acute psychiatric episodes occur during the first two years after the onset of SLE [<a href=\"https://www.uptodate.com/contents/neuropsychiatric-manifestations-of-systemic-lupus-erythematosus/abstract/4,5\" class=\"abstract_t\">4,5</a>].</p><p>The term lupus cerebritis refers to the neuropsychiatric manifestations of lupus that appear to have an organic basis, rather than a specific pathophysiologic mechanism. The distinction between organic and functional causes of some neuropsychiatric symptoms can occasionally be made by assaying for specific autoantibodies.</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Some investigators believe that a strong association exists between the occurrence of neuropsychiatric symptoms and the presence of antineuronal antibodies and other antibodies [<a href=\"https://www.uptodate.com/contents/neuropsychiatric-manifestations-of-systemic-lupus-erythematosus/abstract/6-9\" class=\"abstract_t\">6-9</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Antiribosomal P antibodies have been associated with lupus psychosis and depression by some authors [<a href=\"https://www.uptodate.com/contents/neuropsychiatric-manifestations-of-systemic-lupus-erythematosus/abstract/10,11\" class=\"abstract_t\">10,11</a>]. But this association has not been confirmed by others [<a href=\"https://www.uptodate.com/contents/neuropsychiatric-manifestations-of-systemic-lupus-erythematosus/abstract/9,12\" class=\"abstract_t\">9,12</a>]. (See <a href=\"topic.htm?path=antiribosomal-p-protein-antibodies\" class=\"medical medical_review\">&quot;Antiribosomal P protein antibodies&quot;</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Some data suggest that cognitive defects may be associated with the presence of elevated levels of antineuronal antibodies, antiphospholipid antibodies, or antibodies to N-methyl-D-aspartate (NMDA) receptors [<a href=\"https://www.uptodate.com/contents/neuropsychiatric-manifestations-of-systemic-lupus-erythematosus/abstract/13-15\" class=\"abstract_t\">13-15</a>]. Others have not confirmed these observations [<a href=\"https://www.uptodate.com/contents/neuropsychiatric-manifestations-of-systemic-lupus-erythematosus/abstract/9,16,17\" class=\"abstract_t\">9,16,17</a>].</p><p/><p>A functional (psychologic) process is assumed in a patient with cognitive defects who has none of these antibodies, a negative MRI and EEG, and psychometric testing that &quot;rules out&quot; organic disease.</p><p>The clinical manifestations and treatment of the neuropsychiatric manifestations of CNS lupus will be reviewed here. Other neurologic manifestations of this disease and the diagnostic approach to neuropsychiatric lupus are presented separately. (See <a href=\"topic.htm?path=neurologic-manifestations-of-systemic-lupus-erythematosus\" class=\"medical medical_review\">&quot;Neurologic manifestations of systemic lupus erythematosus&quot;</a> and <a href=\"topic.htm?path=diagnostic-approach-to-the-neuropsychiatric-manifestations-of-systemic-lupus-erythematosus\" class=\"medical medical_review\">&quot;Diagnostic approach to the neuropsychiatric manifestations of systemic lupus erythematosus&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H2\"><span class=\"h1\">PREVALENCE</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>When the American College of Rheumatology case definitions are used to determine the prevalence of neurologic and psychiatric manifestations the following order is noted (from most to least prevalent): cognitive dysfunction, headache, mood disorder, cerebrovascular disease, seizures, polyneuropathy, anxiety, and psychosis [<a href=\"https://www.uptodate.com/contents/neuropsychiatric-manifestations-of-systemic-lupus-erythematosus/abstract/18\" class=\"abstract_t\">18</a>].</p><p class=\"headingAnchor\" id=\"H3\"><span class=\"h1\">PSYCHOSIS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Organic psychosis occurs in approximately five percent of patients with SLE [<a href=\"https://www.uptodate.com/contents/neuropsychiatric-manifestations-of-systemic-lupus-erythematosus/abstract/19,20\" class=\"abstract_t\">19,20</a>], usually within the first year of diagnosis. As an example, one study of 36 patients with primary psychotic events found that 61 percent of the episodes occurred within the first year after the diagnosis of SLE [<a href=\"https://www.uptodate.com/contents/neuropsychiatric-manifestations-of-systemic-lupus-erythematosus/abstract/5\" class=\"abstract_t\">5</a>]. Recurrent episodes occurred in 10 patients at a median of eight months after the initial episode.</p><p>Psychosis is characterized by disordered and bizarre thinking that often includes delusions and hallucinations. Some patients may also present with a fluctuating delirium or &quot;clouding of consciousness,&quot; typically occurring at night [<a href=\"https://www.uptodate.com/contents/neuropsychiatric-manifestations-of-systemic-lupus-erythematosus/abstract/20\" class=\"abstract_t\">20</a>]. Other associated symptoms include a poor attention span, easy distraction, misinterpretation of surroundings, agitation, or combative behavior.</p><p>Symptoms may be caused by corticosteroid therapy.We have observed that auditory hallucinations are usually caused by steroid therapy, while visual and tactile disturbances are most frequently due to SLE. In the latter circumstance, an association has been noted between lupus psychosis and the presence of antibodies to ribosomal P protein [<a href=\"https://www.uptodate.com/contents/neuropsychiatric-manifestations-of-systemic-lupus-erythematosus/abstract/10\" class=\"abstract_t\">10</a>] or to neuronal cells [<a href=\"https://www.uptodate.com/contents/neuropsychiatric-manifestations-of-systemic-lupus-erythematosus/abstract/21\" class=\"abstract_t\">21</a>]. &#160;A systematic review found that glucocorticoid-induced neuropsychiatric disturbances were dose-dependent, with an increased risk with a <a href=\"topic.htm?path=prednisone-drug-information\" class=\"drug drug_general\">prednisone</a> equivalent dose of &ge; 40 <span class=\"nowrap\">mg/day</span>. Symptoms usually occurred during the first six weeks of treatment, and they were more common in women than in men [<a href=\"https://www.uptodate.com/contents/neuropsychiatric-manifestations-of-systemic-lupus-erythematosus/abstract/22\" class=\"abstract_t\">22</a>]. Neuropsychiatric symptoms generally resolve with discontinuation of glucocorticoids [<a href=\"https://www.uptodate.com/contents/neuropsychiatric-manifestations-of-systemic-lupus-erythematosus/abstract/22\" class=\"abstract_t\">22</a>]. &#160; </p><p class=\"headingAnchor\" id=\"H4\"><span class=\"h2\">Treatment</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Psychologic symptoms are best treated with typical antipsychotic drugs (such as <a href=\"topic.htm?path=haloperidol-drug-information\" class=\"drug drug_general\">haloperidol</a>), as well as with active support by health caretakers and family. Oral or intramuscular administration is preferred to intravenous use because clinically significant prolongation of the QT interval may occur more often with the latter route. Use of atypical antipsychotics may be appropriate for patients with multiple risk factors for QT prolongation, including electrolyte imbalance, hypothyroidism, or use of other drugs associated with QT prolongation. (See <a href=\"topic.htm?path=acquired-long-qt-syndrome-definitions-causes-and-pathophysiology\" class=\"medical medical_review\">&quot;Acquired long QT syndrome: Definitions, causes, and pathophysiology&quot;</a>.)</p><p>Neuropsychiatric symptoms due to corticosteroid therapy generally resolve with discontinuation or lowered dose of glucocorticoids [<a href=\"https://www.uptodate.com/contents/neuropsychiatric-manifestations-of-systemic-lupus-erythematosus/abstract/22\" class=\"abstract_t\">22</a>]. &#160; </p><p>Psychosis due to (active) organic involvement by SLE usually responds to steroids. Treatment should be initiated as soon as possible to prevent permanent damage. <a href=\"topic.htm?path=prednisone-drug-information\" class=\"drug drug_general\">Prednisone</a> (1 to 2 <span class=\"nowrap\">mg/kg</span> per day) given for a few weeks in divided doses is usually sufficient. If no improvement is seen within two to three weeks, a trial of cytotoxic therapy (eg, pulse <a href=\"topic.htm?path=cyclophosphamide-drug-information\" class=\"drug drug_general\">cyclophosphamide</a>) is warranted [<a href=\"https://www.uptodate.com/contents/neuropsychiatric-manifestations-of-systemic-lupus-erythematosus/abstract/23-25\" class=\"abstract_t\">23-25</a>]. One study, for example, evaluated the outcome in 31 patients with severe neuropsychiatric lupus who had primarily failed previous therapy with corticosteroids and, in some cases, oral cytotoxic drugs [<a href=\"https://www.uptodate.com/contents/neuropsychiatric-manifestations-of-systemic-lupus-erythematosus/abstract/24\" class=\"abstract_t\">24</a>]. The patients were treated with intravenous pulse cyclophosphamide and, in eight patients, plasmapheresis. Substantial improvement was seen in 61 percent and partial improvement in 29 percent.</p><p><a href=\"topic.htm?path=azathioprine-drug-information\" class=\"drug drug_general\">Azathioprine</a> may be an effective yet safer alternative to continued <a href=\"topic.htm?path=cyclophosphamide-drug-information\" class=\"drug drug_general\">cyclophosphamide</a> for long-term maintenance following recovery from an episode of psychosis. The potential value of such an approach was illustrated in an uncontrolled study of 13 patients with SLE whose psychosis was initially treated with <a href=\"topic.htm?path=prednisone-drug-information\" class=\"drug drug_general\">prednisone</a> (1 <span class=\"nowrap\">mg/kg</span> per day for 8 weeks and then tapered); and oral cyclophosphamide (1 to 2 <span class=\"nowrap\">mg/kg</span> per day) for six months [<a href=\"https://www.uptodate.com/contents/neuropsychiatric-manifestations-of-systemic-lupus-erythematosus/abstract/26\" class=\"abstract_t\">26</a>]. The initial prednisone and cyclophosphamide therapy was followed by azathioprine (1 to 2 <span class=\"nowrap\">mg/kg</span> per day). The psychosis cleared in all patients within 7 months. During an average follow-up of 86 months on azathioprine maintenance, only one patient had a psychotic relapse.</p><p class=\"headingAnchor\" id=\"H5\"><span class=\"h1\">COGNITIVE DEFECTS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Cognitive dysfunction is an organic mental syndrome characterized by any combination of the following symptoms: difficulty in short or long-term memory; impaired judgment and abstract thinking; aphasia; apraxia; agnosia; and personality changes [<a href=\"https://www.uptodate.com/contents/neuropsychiatric-manifestations-of-systemic-lupus-erythematosus/abstract/19,27\" class=\"abstract_t\">19,27</a>]. Cognitive defects are relatively common in patients with SLE, with an incidence ranging from 21 percent to 80 percent in studies using tests such as the Stanford-Binet Intelligence test, the Wechsler Adult Intelligence Scale, the Complex Attention Task, and the Pattern Comparison Task [<a href=\"https://www.uptodate.com/contents/neuropsychiatric-manifestations-of-systemic-lupus-erythematosus/abstract/13,28-31\" class=\"abstract_t\">13,28-31</a>].</p><p>The biologic mechanisms, cognitive assessment, and treatment of cognitive dysfunction has been reviewed [<a href=\"https://www.uptodate.com/contents/neuropsychiatric-manifestations-of-systemic-lupus-erythematosus/abstract/32\" class=\"abstract_t\">32</a>]. The following generalizations can be made regarding the clinical and pathophysiologic characteristics of patients with cognitive defects:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>There is disagreement regarding the association between cognitive dysfunction, and the antibodies implicated in other types of neuropsychiatric CNS lupus. Some studies have found no difference in prevalence of either antineuronal or antiphospholipid antibodies between patients with cognitive dysfunction and normal controls [<a href=\"https://www.uptodate.com/contents/neuropsychiatric-manifestations-of-systemic-lupus-erythematosus/abstract/6\" class=\"abstract_t\">6</a>], while others have found an association with these antibodies [<a href=\"https://www.uptodate.com/contents/neuropsychiatric-manifestations-of-systemic-lupus-erythematosus/abstract/13,14,33-35\" class=\"abstract_t\">13,14,33-35</a>]. Antibodies to ribosomal P protein have been associated with lupus psychosis and depression but not with cognitive dysfunction or psychological distress as assessed by the MMPI test (Minnesota Multiphasic Personality Inventory) [<a href=\"https://www.uptodate.com/contents/neuropsychiatric-manifestations-of-systemic-lupus-erythematosus/abstract/36\" class=\"abstract_t\">36</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The role of cytokines, matrix metalloproteinases, vascular abnormalities, neuropeptides, and endocrine factors have been investigated; no consistent abnormalities have been noted [<a href=\"https://www.uptodate.com/contents/neuropsychiatric-manifestations-of-systemic-lupus-erythematosus/abstract/32\" class=\"abstract_t\">32</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Cognitive dysfunction appears to be evanescent, and is not directly correlated with active disease or corticosteroid therapy [<a href=\"https://www.uptodate.com/contents/neuropsychiatric-manifestations-of-systemic-lupus-erythematosus/abstract/13,29,36,37\" class=\"abstract_t\">13,29,36,37</a>]. However, it is more common in patients with active disease who are receiving corticosteroids [<a href=\"https://www.uptodate.com/contents/neuropsychiatric-manifestations-of-systemic-lupus-erythematosus/abstract/34,38\" class=\"abstract_t\">34,38</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Although it may occur independent of psychologic stress, cognitive dysfunction may be caused or exacerbated by a coexistent psychiatric disorder [<a href=\"https://www.uptodate.com/contents/neuropsychiatric-manifestations-of-systemic-lupus-erythematosus/abstract/13,36,39,40\" class=\"abstract_t\">13,36,39,40</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Two patterns of memory dysfunction have been identified; impaired remote memory appears to be associated with a history of past CNS involvement (suggesting the presence of a residual neurologic deficit), while impaired immediate memory and concentration implies increased disease activity that may represent transient and diffuse CNS effects [<a href=\"https://www.uptodate.com/contents/neuropsychiatric-manifestations-of-systemic-lupus-erythematosus/abstract/41\" class=\"abstract_t\">41</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Associated conditions such as hypertension, multiple small infarcts, and a variety of medications may produce cognitive dysfunction.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Regular use of <a href=\"topic.htm?path=aspirin-drug-information\" class=\"drug drug_general\">aspirin</a> may help prevent cognitive decline, particularly in older patients. A beneficial effect of aspirin was seen in a prospective cohort study of 123 patients [<a href=\"https://www.uptodate.com/contents/neuropsychiatric-manifestations-of-systemic-lupus-erythematosus/abstract/34\" class=\"abstract_t\">34</a>]. However, aspirin use was determined by patient and physician preference and clinical trials are needed to assess the efficacy and safety of this approach. However, the beneficial effects of aspirin on the incidence of cardiovascular events in the general population are well established.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Genetic factors may play a role in susceptibility to cognitive dysfunction in SLE [<a href=\"https://www.uptodate.com/contents/neuropsychiatric-manifestations-of-systemic-lupus-erythematosus/abstract/32,42\" class=\"abstract_t\">32,42</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The neuroimaging of patients with cognitive dysfunction has been an area of active investigation; as yet, none of the available imaging techniques have been predictive of cognitive impairment [<a href=\"https://www.uptodate.com/contents/neuropsychiatric-manifestations-of-systemic-lupus-erythematosus/abstract/32\" class=\"abstract_t\">32</a>].</p><p/><p/><p class=\"headingAnchor\" id=\"H6\"><span class=\"h2\">Treatment</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Treatment is based upon the presumed etiology of the cognitive abnormalities. If due to medications, such as steroids, consider reducing the dose or stopping therapy. If associated with antiphospholipid antibodies, begin anticoagulation. If associated with antineuronal antibodies, a short course of steroids (0.5 <span class=\"nowrap\">mg/kg</span> for a few weeks) may be beneficial [<a href=\"https://www.uptodate.com/contents/neuropsychiatric-manifestations-of-systemic-lupus-erythematosus/abstract/43\" class=\"abstract_t\">43</a>]. Cognitive retraining using a combination of functional strategy training and psychosocial support may be effective in patients with persistent symptoms [<a href=\"https://www.uptodate.com/contents/neuropsychiatric-manifestations-of-systemic-lupus-erythematosus/abstract/44\" class=\"abstract_t\">44</a>].</p><p>The result of a prospective study cited above suggests that regular use of <a href=\"topic.htm?path=aspirin-drug-information\" class=\"drug drug_general\">aspirin</a> may help prevent a decline in cognitive function, particularly in older patients [<a href=\"https://www.uptodate.com/contents/neuropsychiatric-manifestations-of-systemic-lupus-erythematosus/abstract/34\" class=\"abstract_t\">34</a>]. Use of aspirin should also be considered for prevention of cardiovascular events. (See <a href=\"topic.htm?path=coronary-heart-disease-in-systemic-lupus-erythematosus\" class=\"medical medical_review\">&quot;Coronary heart disease in systemic lupus erythematosus&quot;</a>.)</p><p>Criteria for response to treatment of cognitive impairment have been proposed for use in clinical trials [<a href=\"https://www.uptodate.com/contents/neuropsychiatric-manifestations-of-systemic-lupus-erythematosus/abstract/45\" class=\"abstract_t\">45</a>]. A quantitative measure of cognitive function may be obtained using a combination of formal assessments (eg, the ACR neuropsychological battery and the Cognitive Symptoms Inventory). Serial assessments of cognitive function can also be used in clinical practice.</p><p class=\"headingAnchor\" id=\"H7\"><span class=\"h1\">DEMENTIA</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Dementia is characterized by severe cognitive dysfunction, resulting in impaired memory, abstract thinking, and a decreased ability to perform simple manual tasks. The patient may also have difficulty making decisions or controlling impulses. This syndrome in patients with lupus can reflect multiple small ischemic strokes caused by antiphospholipid antibodies [<a href=\"https://www.uptodate.com/contents/neuropsychiatric-manifestations-of-systemic-lupus-erythematosus/abstract/46,47\" class=\"abstract_t\">46,47</a>].</p><p>The exact therapeutic regimen is unclear. Although symptoms occasionally abate without treatment, the following general recommendations can be made:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Dementia due to multiple cerebral infarctions may be worsened by high dose corticosteroids. Consideration should be given to discontinuing or lowering the dose of corticosteroids and other medications that may aggravate symptoms, including nonsteroidal antiinflammatory drugs, antimalarial drugs, and antianxiety drugs [<a href=\"https://www.uptodate.com/contents/neuropsychiatric-manifestations-of-systemic-lupus-erythematosus/abstract/48\" class=\"abstract_t\">48</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Coexisting depression should be treated by conventional means.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>One small randomized, controlled study showed a statistically significant improvement in cognition in women with mild SLE treated with low dose <a href=\"topic.htm?path=prednisone-drug-information\" class=\"drug drug_general\">prednisone</a> (0.5 <span class=\"nowrap\">mg/kg</span> per day) [<a href=\"https://www.uptodate.com/contents/neuropsychiatric-manifestations-of-systemic-lupus-erythematosus/abstract/43\" class=\"abstract_t\">43</a>]. Although these results are not directly applicable to dementia, we recommend a trial using the same regimen if the above modalities are ineffective.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Support by family and health professionals, plus reminder prompts, will usually help patients deal with this problem.</p><p/><p/><p class=\"headingAnchor\" id=\"H8\"><span class=\"h1\">SECONDARY PSYCHIATRIC MANIFESTATIONS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Although depression, anxiety and manic behavior may occasionally reflect organic involvement, these symptoms are more typically functional [<a href=\"https://www.uptodate.com/contents/neuropsychiatric-manifestations-of-systemic-lupus-erythematosus/abstract/49\" class=\"abstract_t\">49</a>]. The distinction between organic and functional disease is based upon psychological testing, followed by a series of studies that may include CT scan, magnetic resonance imaging, SPECT scans, evoked potentials, electroencephalograms, cerebrospinal fluid analysis, and a psychiatric interview when the initial studies are equivocal [<a href=\"https://www.uptodate.com/contents/neuropsychiatric-manifestations-of-systemic-lupus-erythematosus/abstract/27,39\" class=\"abstract_t\">27,39</a>]. (See <a href=\"topic.htm?path=diagnostic-approach-to-the-neuropsychiatric-manifestations-of-systemic-lupus-erythematosus\" class=\"medical medical_review\">&quot;Diagnostic approach to the neuropsychiatric manifestations of systemic lupus erythematosus&quot;</a>.)</p><p>The specific psychologic symptoms that occur may include phobias, depression, anxiety, mania, paresthesias, headaches, mood swings, agoraphobia (with and without panic), social phobia, alcohol abuse, cognitive problems such as poor concentration, impaired memory, and difficulty with word finding or spatial orientation [<a href=\"https://www.uptodate.com/contents/neuropsychiatric-manifestations-of-systemic-lupus-erythematosus/abstract/13,50\" class=\"abstract_t\">13,50</a>]. The individual pattern that develops usually reflects the patients coping mechanisms used to deal with the stress of chronic illness, rather than a specific disease process.</p><p>Interactions between the patient and physician can occasionally adversely effect symptom resolution. Patients often relate a long history of frustration in obtaining the proper diagnosis [<a href=\"https://www.uptodate.com/contents/neuropsychiatric-manifestations-of-systemic-lupus-erythematosus/abstract/14\" class=\"abstract_t\">14</a>], and physicians may have difficulty dealing with patients who have neuropsychiatric symptoms and signs [<a href=\"https://www.uptodate.com/contents/neuropsychiatric-manifestations-of-systemic-lupus-erythematosus/abstract/51\" class=\"abstract_t\">51</a>].</p><p class=\"headingAnchor\" id=\"H9\"><span class=\"h2\">Depression</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The most common psychologic symptom in patients with SLE is depression [<a href=\"https://www.uptodate.com/contents/neuropsychiatric-manifestations-of-systemic-lupus-erythematosus/abstract/31,52,53\" class=\"abstract_t\">31,52,53</a>]. Depressive symptoms usually begin acutely [<a href=\"https://www.uptodate.com/contents/neuropsychiatric-manifestations-of-systemic-lupus-erythematosus/abstract/54\" class=\"abstract_t\">54</a>]. They reflect the patient's reaction to chronic illness and the significant lifestyle limitations that must be endured, including difficulties with pregnancy, fatigue, limited sun exposure, and chronic medication use, <span class=\"nowrap\">and/or</span> coping styles and limited social support [<a href=\"https://www.uptodate.com/contents/neuropsychiatric-manifestations-of-systemic-lupus-erythematosus/abstract/52,53\" class=\"abstract_t\">52,53</a>]. There may also be an organic basis in some cases. Some depressed patients, for example, have elevated levels of certain autoantibodies or are more prone to have associated illnesses.</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>An association has been reported between severe depression and anti-ribosomal P antibodies, and antibodies to NMDA-receptors, but not with other antibodies [<a href=\"https://www.uptodate.com/contents/neuropsychiatric-manifestations-of-systemic-lupus-erythematosus/abstract/1,16,54,55\" class=\"abstract_t\">1,16,54,55</a>]. Elevated levels of antibodies to ribosomal P proteins have been found in 70 to 88 percent of such patients by some investigators [<a href=\"https://www.uptodate.com/contents/neuropsychiatric-manifestations-of-systemic-lupus-erythematosus/abstract/1,55\" class=\"abstract_t\">1,55</a>]; others have failed to observe an association between depression and antibodies to NMDA-receptors [<a href=\"https://www.uptodate.com/contents/neuropsychiatric-manifestations-of-systemic-lupus-erythematosus/abstract/17\" class=\"abstract_t\">17</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>One study of 71 patients with SLE noted an association between depression and both neuropsychiatric lupus and secondary Sj&ouml;gren's syndrome [<a href=\"https://www.uptodate.com/contents/neuropsychiatric-manifestations-of-systemic-lupus-erythematosus/abstract/56\" class=\"abstract_t\">56</a>]. Patients with neuropsychiatric lupus had an adjusted odds ratio of 3.43 for depressive symptoms, while those with secondary Sj&ouml;gren's syndrome had an adjusted odds ratio of 2.97.</p><p/><p>Most patients recover within one year with the help of family, friends, physicians, <span class=\"nowrap\">and/or</span> other professionals. Other patients may incorporate the depression into their personality, thereby developing many concurrent (psycho)somatic complaints such as insomnia, anorexia, constipation, myalgia, arthralgia, and fatigue [<a href=\"https://www.uptodate.com/contents/neuropsychiatric-manifestations-of-systemic-lupus-erythematosus/abstract/57,58\" class=\"abstract_t\">57,58</a>]. Patients may also develop &quot;psychotic&quot; features, with increasing despair, loss of hope, and even suicidal tendencies; prompt psychiatric intervention is essential in this circumstance.</p><p class=\"headingAnchor\" id=\"H10\"><span class=\"h2\">Anxiety</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Following the initial diagnosis of SLE, or after an acute exacerbation, some patients display symptoms of anxiety, either instead of or in addition to depression. The patient may become anxious about a variety of possible consequences of their illness, including disfigurement, disability, dependency, loss of a job, social isolation, or death.</p><p>Anxiety may be manifested by palpitations, diarrhea, sweating, hyperventilation, dizzy spells, difficulty with speech, memory, or words, fear of &quot;going crazy,&quot; or headaches. This state may deteriorate into obsessive-compulsive behavior, phobias, hypochondriasis, sleep disturbances, and a reduction in social contacts and interaction [<a href=\"https://www.uptodate.com/contents/neuropsychiatric-manifestations-of-systemic-lupus-erythematosus/abstract/55\" class=\"abstract_t\">55</a>].</p><p class=\"headingAnchor\" id=\"H11\"><span class=\"h2\">Other psychiatric manifestations</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Some patients develop manic behavior or an organic personality disorder. The former is characterized by a marked increase in energy and activity, irritability, and sleeplessness. This behavior is usually due to high doses of steroids. A sudden marked change in personality may also occur due to any of the causes discussed above, with symptoms including apathy, indifference, emotional lability, sexual indiscretions, verbosity, religiosity, <span class=\"nowrap\">and/or</span> aggressiveness [<a href=\"https://www.uptodate.com/contents/neuropsychiatric-manifestations-of-systemic-lupus-erythematosus/abstract/20\" class=\"abstract_t\">20</a>].</p><p class=\"headingAnchor\" id=\"H10836546\"><span class=\"h1\">ACKNOWLEDGMENT</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The editors of UpToDate, Inc. would like to acknowledge Shahram Khoshbin, MD, who contributed to earlier versions of this topic review.</p></div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\"><li><a href=\"https://www.uptodate.com/contents/neuropsychiatric-manifestations-of-systemic-lupus-erythematosus/abstract/1\" class=\"nounderline abstract_t\">West SG, Emlen W, Wener MH, Kotzin BL. Neuropsychiatric lupus erythematosus: a 10-year prospective study on the value of diagnostic tests. Am J Med 1995; 99:153.</a></li><li><a href=\"https://www.uptodate.com/contents/neuropsychiatric-manifestations-of-systemic-lupus-erythematosus/abstract/2\" class=\"nounderline abstract_t\">The American College of Rheumatology nomenclature and case definitions for neuropsychiatric lupus syndromes. Arthritis Rheum 1999; 42:599.</a></li><li><a href=\"https://www.uptodate.com/contents/neuropsychiatric-manifestations-of-systemic-lupus-erythematosus/abstract/3\" class=\"nounderline abstract_t\">Miguel EC, Pereira RM, Pereira CA, et al. Psychiatric manifestations of systemic lupus erythematosus: clinical features, symptoms, and signs of central nervous system activity in 43 patients. Medicine (Baltimore) 1994; 73:224.</a></li><li><a href=\"https://www.uptodate.com/contents/neuropsychiatric-manifestations-of-systemic-lupus-erythematosus/abstract/4\" class=\"nounderline abstract_t\">Sibley JT, Olszynski WP, Decoteau WE, Sundaram MB. The incidence and prognosis of central nervous system disease in systemic lupus erythematosus. J Rheumatol 1992; 19:47.</a></li><li><a href=\"https://www.uptodate.com/contents/neuropsychiatric-manifestations-of-systemic-lupus-erythematosus/abstract/5\" class=\"nounderline abstract_t\">Ward MM, Studenski S. The time course of acute psychiatric episodes in systemic lupus erythematosus. J Rheumatol 1991; 18:535.</a></li><li><a href=\"https://www.uptodate.com/contents/neuropsychiatric-manifestations-of-systemic-lupus-erythematosus/abstract/6\" class=\"nounderline abstract_t\">Hanly JG, Fisk JD, Eastwood B. Brain reactive autoantibodies and cognitive impairment in systemic lupus erythematosus. Lupus 1994; 3:193.</a></li><li><a href=\"https://www.uptodate.com/contents/neuropsychiatric-manifestations-of-systemic-lupus-erythematosus/abstract/7\" class=\"nounderline abstract_t\">Denburg SD, Behmann SA, Carbotte RM, Denburg JA. Lymphocyte antigens in neuropsychiatric systemic lupus erythematosus. Relationship of lymphocyte antibody specificities to clinical disease. Arthritis Rheum 1994; 37:369.</a></li><li><a href=\"https://www.uptodate.com/contents/neuropsychiatric-manifestations-of-systemic-lupus-erythematosus/abstract/8\" class=\"nounderline abstract_t\">Denburg JA, Behmann SA. Lymphocyte and neuronal antigens in neuropsychiatric lupus: presence of an elutable, immunoprecipitable lymphocyte/neuronal 52 kd reactivity. Ann Rheum Dis 1994; 53:304.</a></li><li><a href=\"https://www.uptodate.com/contents/neuropsychiatric-manifestations-of-systemic-lupus-erythematosus/abstract/9\" class=\"nounderline abstract_t\">Conti F, Alessandri C, Bompane D, et al. Autoantibody profile in systemic lupus erythematosus with psychiatric manifestations: a role for anti-endothelial-cell antibodies. Arthritis Res Ther 2004; 6:R366.</a></li><li><a href=\"https://www.uptodate.com/contents/neuropsychiatric-manifestations-of-systemic-lupus-erythematosus/abstract/10\" class=\"nounderline abstract_t\">Bonfa E, Golombek SJ, Kaufman LD, et al. Association between lupus psychosis and anti-ribosomal P protein antibodies. N Engl J Med 1987; 317:265.</a></li><li><a href=\"https://www.uptodate.com/contents/neuropsychiatric-manifestations-of-systemic-lupus-erythematosus/abstract/11\" class=\"nounderline abstract_t\">Isshi K, Hirohata S. Association of anti-ribosomal P protein antibodies with neuropsychiatric systemic lupus erythematosus. Arthritis Rheum 1996; 39:1483.</a></li><li><a href=\"https://www.uptodate.com/contents/neuropsychiatric-manifestations-of-systemic-lupus-erythematosus/abstract/12\" class=\"nounderline abstract_t\">Gerli R, Caponi L, Tincani A, et al. Clinical and serological associations of ribosomal P autoantibodies in systemic lupus erythematosus: prospective evaluation in a large cohort of Italian patients. Rheumatology (Oxford) 2002; 41:1357.</a></li><li><a href=\"https://www.uptodate.com/contents/neuropsychiatric-manifestations-of-systemic-lupus-erythematosus/abstract/13\" class=\"nounderline abstract_t\">Carbotte RM, Denburg SD, Denburg JA. Cognitive deficit associated with rheumatic diseases: neuropsychological perspectives. Arthritis Rheum 1995; 38:1363.</a></li><li><a href=\"https://www.uptodate.com/contents/neuropsychiatric-manifestations-of-systemic-lupus-erythematosus/abstract/14\" class=\"nounderline abstract_t\">Hanly JG, Hong C, Smith S, Fisk JD. A prospective analysis of cognitive function and anticardiolipin antibodies in systemic lupus erythematosus. Arthritis Rheum 1999; 42:728.</a></li><li><a href=\"https://www.uptodate.com/contents/neuropsychiatric-manifestations-of-systemic-lupus-erythematosus/abstract/15\" class=\"nounderline abstract_t\">Omdal R, Brokstad K, Waterloo K, et al. Neuropsychiatric disturbances in SLE are associated with antibodies against NMDA receptors. Eur J Neurol 2005; 12:392.</a></li><li><a href=\"https://www.uptodate.com/contents/neuropsychiatric-manifestations-of-systemic-lupus-erythematosus/abstract/16\" class=\"nounderline abstract_t\">Lapteva L, Nowak M, Yarboro CH, et al. Anti-N-methyl-D-aspartate receptor antibodies, cognitive dysfunction, and depression in systemic lupus erythematosus. Arthritis Rheum 2006; 54:2505.</a></li><li><a href=\"https://www.uptodate.com/contents/neuropsychiatric-manifestations-of-systemic-lupus-erythematosus/abstract/17\" class=\"nounderline abstract_t\">Harrison MJ, Ravdin LD, Lockshin MD. Relationship between serum NR2a antibodies and cognitive dysfunction in systemic lupus erythematosus. Arthritis Rheum 2006; 54:2515.</a></li><li><a href=\"https://www.uptodate.com/contents/neuropsychiatric-manifestations-of-systemic-lupus-erythematosus/abstract/18\" class=\"nounderline abstract_t\">Hanly JG. ACR classification criteria for systemic lupus erythematosus: limitations and revisions to neuropsychiatric variables. Lupus 2004; 13:861.</a></li><li class=\"breakAll\">Rogers MP. Psychiatric Aspects. In: The Clinical Management of Systemic Lupus Erythematosus, 2nd ed, Schur PH (Ed), Lippincott, Philadelphia 1996.</li><li class=\"breakAll\">Perry SW. Psychiatric aspects of systemic lupus erythematosus. In: Systemic Lupus Erythematosus, Lahita RG (Ed), John Wiley and Sons, New York 1987.</li><li><a href=\"https://www.uptodate.com/contents/neuropsychiatric-manifestations-of-systemic-lupus-erythematosus/abstract/21\" class=\"nounderline abstract_t\">Bluestein HG, Williams GW, Steinberg AD. Cerebrospinal fluid antibodies to neuronal cells: association with neuropsychiatric manifestations of systemic lupus erythematosus. Am J Med 1981; 70:240.</a></li><li><a href=\"https://www.uptodate.com/contents/neuropsychiatric-manifestations-of-systemic-lupus-erythematosus/abstract/22\" class=\"nounderline abstract_t\">Bhangle SD, Kramer N, Rosenstein ED. Corticosteroid-induced neuropsychiatric disorders: review and contrast with neuropsychiatric lupus. Rheumatol Int 2013; 33:1923.</a></li><li><a href=\"https://www.uptodate.com/contents/neuropsychiatric-manifestations-of-systemic-lupus-erythematosus/abstract/23\" class=\"nounderline abstract_t\">Schroeder JO, Euler HH, L&ouml;ffler H. Synchronization of plasmapheresis and pulse cyclophosphamide in severe systemic lupus erythematosus. Ann Intern Med 1987; 107:344.</a></li><li><a href=\"https://www.uptodate.com/contents/neuropsychiatric-manifestations-of-systemic-lupus-erythematosus/abstract/24\" class=\"nounderline abstract_t\">Neuwelt CM, Lacks S, Kaye BR, et al. Role of intravenous cyclophosphamide in the treatment of severe neuropsychiatric systemic lupus erythematosus. Am J Med 1995; 98:32.</a></li><li><a href=\"https://www.uptodate.com/contents/neuropsychiatric-manifestations-of-systemic-lupus-erythematosus/abstract/25\" class=\"nounderline abstract_t\">Boumpas DT, Yamada H, Patronas NJ, et al. Pulse cyclophosphamide for severe neuropsychiatric lupus. Q J Med 1991; 81:975.</a></li><li><a href=\"https://www.uptodate.com/contents/neuropsychiatric-manifestations-of-systemic-lupus-erythematosus/abstract/26\" class=\"nounderline abstract_t\">Mok CC, Lau CS, Wong RW. Treatment of lupus psychosis with oral cyclophosphamide followed by azathioprine maintenance: an open-label study. Am J Med 2003; 115:59.</a></li><li class=\"breakAll\">Rogers, MP, Liang, MH, Waterhouse, E, et al. Disturbed cognition and systemic lupus erythematosus: A subset of central nervous system lupus. Submitted for publication.</li><li><a href=\"https://www.uptodate.com/contents/neuropsychiatric-manifestations-of-systemic-lupus-erythematosus/abstract/28\" class=\"nounderline abstract_t\">Hay EM. Psychiatric disorder and cognitive impairment in SLE. Lupus 1994; 3:145.</a></li><li><a href=\"https://www.uptodate.com/contents/neuropsychiatric-manifestations-of-systemic-lupus-erythematosus/abstract/29\" class=\"nounderline abstract_t\">Hanly JG, Fisk JD, Sherwood G, Eastwood B. Clinical course of cognitive dysfunction in systemic lupus erythematosus. J Rheumatol 1994; 21:1825.</a></li><li><a href=\"https://www.uptodate.com/contents/neuropsychiatric-manifestations-of-systemic-lupus-erythematosus/abstract/30\" class=\"nounderline abstract_t\">Ainiala H, Loukkola J, Peltola J, et al. The prevalence of neuropsychiatric syndromes in systemic lupus erythematosus. Neurology 2001; 57:496.</a></li><li><a href=\"https://www.uptodate.com/contents/neuropsychiatric-manifestations-of-systemic-lupus-erythematosus/abstract/31\" class=\"nounderline abstract_t\">Kozora E, Ellison MC, West S. Depression, fatigue, and pain in systemic lupus erythematosus (SLE): relationship to the American College of Rheumatology SLE neuropsychological battery. Arthritis Rheum 2006; 55:628.</a></li><li><a href=\"https://www.uptodate.com/contents/neuropsychiatric-manifestations-of-systemic-lupus-erythematosus/abstract/32\" class=\"nounderline abstract_t\">Kozora E, Hanly JG, Lapteva L, Filley CM. Cognitive dysfunction in systemic lupus erythematosus: past, present, and future. Arthritis Rheum 2008; 58:3286.</a></li><li><a href=\"https://www.uptodate.com/contents/neuropsychiatric-manifestations-of-systemic-lupus-erythematosus/abstract/33\" class=\"nounderline abstract_t\">Menon S, Jameson-Shortall E, Newman SP, et al. A longitudinal study of anticardiolipin antibody levels and cognitive functioning in systemic lupus erythematosus. Arthritis Rheum 1999; 42:735.</a></li><li><a href=\"https://www.uptodate.com/contents/neuropsychiatric-manifestations-of-systemic-lupus-erythematosus/abstract/34\" class=\"nounderline abstract_t\">McLaurin EY, Holliday SL, Williams P, Brey RL. Predictors of cognitive dysfunction in patients with systemic lupus erythematosus. Neurology 2005; 64:297.</a></li><li><a href=\"https://www.uptodate.com/contents/neuropsychiatric-manifestations-of-systemic-lupus-erythematosus/abstract/35\" class=\"nounderline abstract_t\">Tektonidou MG, Varsou N, Kotoulas G, et al. Cognitive deficits in patients with antiphospholipid syndrome: association with clinical, laboratory, and brain magnetic resonance imaging findings. Arch Intern Med 2006; 166:2278.</a></li><li><a href=\"https://www.uptodate.com/contents/neuropsychiatric-manifestations-of-systemic-lupus-erythematosus/abstract/36\" class=\"nounderline abstract_t\">Kozora E, Thompson LL, West SG, Kotzin BL. Analysis of cognitive and psychological deficits in systemic lupus erythematosus patients without overt central nervous system disease. Arthritis Rheum 1996; 39:2035.</a></li><li><a href=\"https://www.uptodate.com/contents/neuropsychiatric-manifestations-of-systemic-lupus-erythematosus/abstract/37\" class=\"nounderline abstract_t\">Hay EM, Black D, Huddy A, et al. Psychiatric disorder and cognitive impairment in systemic lupus erythematosus. Arthritis Rheum 1992; 35:411.</a></li><li><a href=\"https://www.uptodate.com/contents/neuropsychiatric-manifestations-of-systemic-lupus-erythematosus/abstract/38\" class=\"nounderline abstract_t\">Hanly JG, Fisk JD, Sherwood G, et al. Cognitive impairment in patients with systemic lupus erythematosus. J Rheumatol 1992; 19:562.</a></li><li><a href=\"https://www.uptodate.com/contents/neuropsychiatric-manifestations-of-systemic-lupus-erythematosus/abstract/39\" class=\"nounderline abstract_t\">Carbotte RM, Denburg SD, Denburg JA. Prevalence of cognitive impairment in systemic lupus erythematosus. J Nerv Ment Dis 1986; 174:357.</a></li><li><a href=\"https://www.uptodate.com/contents/neuropsychiatric-manifestations-of-systemic-lupus-erythematosus/abstract/40\" class=\"nounderline abstract_t\">Hay EM, Huddy A, Black D, et al. A prospective study of psychiatric disorder and cognitive function in systemic lupus erythematosus. Ann Rheum Dis 1994; 53:298.</a></li><li><a href=\"https://www.uptodate.com/contents/neuropsychiatric-manifestations-of-systemic-lupus-erythematosus/abstract/41\" class=\"nounderline abstract_t\">Fisk JD, Eastwood B, Sherwood G, Hanly JG. Patterns of cognitive impairment in patients with systemic lupus erythematosus. Br J Rheumatol 1993; 32:458.</a></li><li><a href=\"https://www.uptodate.com/contents/neuropsychiatric-manifestations-of-systemic-lupus-erythematosus/abstract/42\" class=\"nounderline abstract_t\">Oroszi G, Lapteva L, Davis E, et al. The Met66 allele of the functional Val66Met polymorphism in the brain-derived neurotrophic factor gene confers protection against neurocognitive dysfunction in systemic lupus erythematosus. Ann Rheum Dis 2006; 65:1330.</a></li><li><a href=\"https://www.uptodate.com/contents/neuropsychiatric-manifestations-of-systemic-lupus-erythematosus/abstract/43\" class=\"nounderline abstract_t\">Denburg SD, Carbotte RM, Denburg JA. Corticosteroids and neuropsychological functioning in patients with systemic lupus erythematosus. Arthritis Rheum 1994; 37:1311.</a></li><li><a href=\"https://www.uptodate.com/contents/neuropsychiatric-manifestations-of-systemic-lupus-erythematosus/abstract/44\" class=\"nounderline abstract_t\">Harrison MJ, Morris KA, Horton R, et al. Results of intervention for lupus patients with self-perceived cognitive difficulties. Neurology 2005; 65:1325.</a></li><li><a href=\"https://www.uptodate.com/contents/neuropsychiatric-manifestations-of-systemic-lupus-erythematosus/abstract/45\" class=\"nounderline abstract_t\">Ad Hoc Committee on Lupus Response Criteria: Cognition Sub-committee, Mikdashi JA, Esdaile JM, et al. Proposed response criteria for neurocognitive impairment in systemic lupus erythematosus clinical trials. Lupus 2007; 16:418.</a></li><li><a href=\"https://www.uptodate.com/contents/neuropsychiatric-manifestations-of-systemic-lupus-erythematosus/abstract/46\" class=\"nounderline abstract_t\">West SG. Neuropsychiatric lupus. Rheum Dis Clin North Am 1994; 20:129.</a></li><li><a href=\"https://www.uptodate.com/contents/neuropsychiatric-manifestations-of-systemic-lupus-erythematosus/abstract/47\" class=\"nounderline abstract_t\">Asherson RA, Mercey D, Phillips G, et al. Recurrent stroke and multi-infarct dementia in systemic lupus erythematosus: association with antiphospholipid antibodies. Ann Rheum Dis 1987; 46:605.</a></li><li><a href=\"https://www.uptodate.com/contents/neuropsychiatric-manifestations-of-systemic-lupus-erythematosus/abstract/48\" class=\"nounderline abstract_t\">Hoppmann RA, Peden JG, Ober SK. Central nervous system side effects of nonsteroidal anti-inflammatory drugs. Aseptic meningitis, psychosis, and cognitive dysfunction. Arch Intern Med 1991; 151:1309.</a></li><li><a href=\"https://www.uptodate.com/contents/neuropsychiatric-manifestations-of-systemic-lupus-erythematosus/abstract/49\" class=\"nounderline abstract_t\">Jennekens FG, Kater L. The central nervous system in systemic lupus erythematosus. Part 1. Clinical syndromes: a literature investigation. Rheumatology (Oxford) 2002; 41:605.</a></li><li><a href=\"https://www.uptodate.com/contents/neuropsychiatric-manifestations-of-systemic-lupus-erythematosus/abstract/50\" class=\"nounderline abstract_t\">L&iacute;ndal E, Thorlacius S, Steinsson K, Stef&aacute;nsson JG. Psychiatric disorders among subjects with systemic lupus erythematosus in an unselected population. Scand J Rheumatol 1995; 24:346.</a></li><li><a href=\"https://www.uptodate.com/contents/neuropsychiatric-manifestations-of-systemic-lupus-erythematosus/abstract/51\" class=\"nounderline abstract_t\">Goodwin JM, Goodwin JS, Kellner R. Psychiatric symptoms in disliked medical patients. JAMA 1979; 241:1117.</a></li><li><a href=\"https://www.uptodate.com/contents/neuropsychiatric-manifestations-of-systemic-lupus-erythematosus/abstract/52\" class=\"nounderline abstract_t\">Kozora E, Ellison MC, Waxmonsky JA, et al. Major life stress, coping styles, and social support in relation to psychological distress in patients with systemic lupus erythematosus. Lupus 2005; 14:363.</a></li><li><a href=\"https://www.uptodate.com/contents/neuropsychiatric-manifestations-of-systemic-lupus-erythematosus/abstract/53\" class=\"nounderline abstract_t\">Jump RL, Robinson ME, Armstrong AE, et al. Fatigue in systemic lupus erythematosus: contributions of disease activity, pain, depression, and perceived social support. J Rheumatol 2005; 32:1699.</a></li><li><a href=\"https://www.uptodate.com/contents/neuropsychiatric-manifestations-of-systemic-lupus-erythematosus/abstract/54\" class=\"nounderline abstract_t\">Shortall E, Isenberg D, Newman SP. Factors associated with mood and mood disorders in SLE. Lupus 1995; 4:272.</a></li><li><a href=\"https://www.uptodate.com/contents/neuropsychiatric-manifestations-of-systemic-lupus-erythematosus/abstract/55\" class=\"nounderline abstract_t\">Schneebaum AB, Singleton JD, West SG, et al. Association of psychiatric manifestations with antibodies to ribosomal P proteins in systemic lupus erythematosus. Am J Med 1991; 90:54.</a></li><li><a href=\"https://www.uptodate.com/contents/neuropsychiatric-manifestations-of-systemic-lupus-erythematosus/abstract/56\" class=\"nounderline abstract_t\">Utset TO, Golden M, Siberry G, et al. Depressive symptoms in patients with systemic lupus erythematosus: association with central nervous system lupus and Sj&ouml;gren's syndrome. J Rheumatol 1994; 21:2039.</a></li><li><a href=\"https://www.uptodate.com/contents/neuropsychiatric-manifestations-of-systemic-lupus-erythematosus/abstract/57\" class=\"nounderline abstract_t\">McKinley PS, Ouellette SC, Winkel GH. The contributions of disease activity, sleep patterns, and depression to fatigue in systemic lupus erythematosus. A proposed model. Arthritis Rheum 1995; 38:826.</a></li><li><a href=\"https://www.uptodate.com/contents/neuropsychiatric-manifestations-of-systemic-lupus-erythematosus/abstract/58\" class=\"nounderline abstract_t\">Krupp LB, LaRocca NG, Muir J, Steinberg AD. A study of fatigue in systemic lupus erythematosus. J Rheumatol 1990; 17:1450.</a></li></ol></div><div id=\"topicVersionRevision\">Topic 4863 Version 8.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul id=\"innerOutline\"><li><a href=\"#H1\" id=\"outline-link-H1\">INTRODUCTION</a></li><li><a href=\"#H2\" id=\"outline-link-H2\">PREVALENCE</a></li><li><a href=\"#H3\" id=\"outline-link-H3\">PSYCHOSIS</a><ul><li><a href=\"#H4\" id=\"outline-link-H4\">Treatment</a></li></ul></li><li><a href=\"#H5\" id=\"outline-link-H5\">COGNITIVE DEFECTS</a><ul><li><a href=\"#H6\" id=\"outline-link-H6\">Treatment</a></li></ul></li><li><a href=\"#H7\" id=\"outline-link-H7\">DEMENTIA</a></li><li><a href=\"#H8\" id=\"outline-link-H8\">SECONDARY PSYCHIATRIC MANIFESTATIONS</a><ul><li><a href=\"#H9\" id=\"outline-link-H9\">Depression</a></li><li><a href=\"#H10\" id=\"outline-link-H10\">Anxiety</a></li><li><a href=\"#H11\" id=\"outline-link-H11\">Other psychiatric manifestations</a></li></ul></li><li><a href=\"#H10836546\" id=\"outline-link-H10836546\">ACKNOWLEDGMENT</a></li><li><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"NEURO/4863|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=RHEUM/51238\" class=\"graphic graphic_table\">- ACR neuropsychiatric SLE</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li class=\"plainItem\"><a href=\"topic.htm?path=acquired-long-qt-syndrome-definitions-causes-and-pathophysiology\" class=\"medical medical_review\">Acquired long QT syndrome: Definitions, causes, and pathophysiology</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=antiribosomal-p-protein-antibodies\" class=\"medical medical_review\">Antiribosomal P protein antibodies</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=coronary-heart-disease-in-systemic-lupus-erythematosus\" class=\"medical medical_review\">Coronary heart disease in systemic lupus erythematosus</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=diagnostic-approach-to-the-neuropsychiatric-manifestations-of-systemic-lupus-erythematosus\" class=\"medical medical_review\">Diagnostic approach to the neuropsychiatric manifestations of systemic lupus erythematosus</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=neurologic-manifestations-of-systemic-lupus-erythematosus\" class=\"medical medical_review\">Neurologic manifestations of systemic lupus erythematosus</a></li></ul></div></div>","javascript":null}